Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA llourdes@iu.edu.
Laura S
LS
Lourdes
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Shadia I
SI
Jalal
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Nasser
N
Hanna
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
D047428:Protein Kinase Inhibitors; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors